Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiora Pharmaceuticals (KPRX) Debt to Equity (2020 - 2023)

Kiora Pharmaceuticals (KPRX) has disclosed Debt to Equity for 5 consecutive years, with $0.06 as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Debt to Equity rose 104.86% year-over-year to $0.06, compared with a TTM value of $0.06 through Sep 2023, up 104.86%, and an annual FY2020 reading of $0.03, changed N/A over the prior year.
  • Debt to Equity was $0.06 for Q3 2023 at Kiora Pharmaceuticals, up from $0.02 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.06 in Q3 2023 and bottomed at $0.02 in Q1 2021.
  • Average Debt to Equity over 4 years is $0.03, with a median of $0.03 recorded in 2022.
  • Peak annual rise in Debt to Equity hit 104.86% in 2023, while the deepest fall reached 33.21% in 2023.
  • Year by year, Debt to Equity stood at $0.03 in 2020, then crashed by 39.13% to $0.02 in 2021, then skyrocketed by 71.33% to $0.03 in 2022, then soared by 104.86% to $0.06 in 2023.
  • Business Quant data shows Debt to Equity for KPRX at $0.06 in Q3 2023, $0.02 in Q2 2023, and $0.03 in Q1 2023.